Towards Predicting the Response of a Solid Tumour to Chemotherapy and Radiotherapy Treatments: Clinical Insights from a Computational Model

Por Powathil, Gibin G., Adamson, Douglas J. A., Chaplain, Mark A. J.
Publicado em 2013

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover

Por Wilson, Caroline, Gossiel, Fatma, Leonard, Robert, Anderson, Richard A, Adamson, Douglas J A, Thomas, Geraldine, Coleman, Robert E
Publicado no J Bone Oncol (2016)

Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT

Por Coombs, Nathan J, Coombs, Joel M, Vaidya, Uma J, Singer, Julian, Bulsara, Max, Tobias, Jeffrey S, Wenz, Frederik, Joseph, David J, Brown, Douglas A, Rainsbury, Richard, Davidson, Tim, Adamson, Douglas J A, Massarut, Samuele, Morgan, David, Potyka, Ingrid, Corica, Tammy, Falzon, Mary, Williams, Norman, Baum, Michael, Vaidya, Jayant S
Publicado no BMJ Open (2016)

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Por Dalgleish, Angus G, Stebbing, Justin, Adamson, Douglas J A, Arif, Seema Safia, Bidoli, Paolo, Chang, David, Cheeseman, Sue, Diaz-Beveridge, Robert, Fernandez-Martos, Carlos, Glynne-Jones, Rob, Granetto, Cristina, Massuti, Bartomeu, McAdam, Karen, McDermott, Raymond, Martín, Andrés J Muñoz, Papamichael, Demetris, Pazo-Cid, Roberto, Vieitez, Jose M, Zaniboni, Alberto, Carroll, Kevin J, Wagle, Shama, Gaya, Andrew, Mudan, Satvinder S
Publicado no Br J Cancer (2016)